Form 8-K - Current report:
SEC Accession No. 0001214659-25-006405
Filing Date
2025-04-25
Accepted
2025-04-25 16:30:45
Documents
13
Period of Report
2025-04-25
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 i4252528k.htm   iXBRL 8-K 36113
  Complete submission text file 0001214659-25-006405.txt   214112

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE alzn-20250425.xsd EX-101.SCH 2990
3 XBRL LABEL FILE alzn-20250425_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE alzn-20250425_pre.xml EX-101.PRE 22342
15 EXTRACTED XBRL INSTANCE DOCUMENT i4252528k_htm.xml XML 3914
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 25874603
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)